Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
The regulatory environment for compounded GLP-1 medications is actively evolving as of May 2026
SPMXC0040 3.2 out of 5 Customer Rating Earn Full Throttle Rewards With Every Purchase
Phase 2 trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) reported mean weight reductions of up to approximately 24% over 48 weeks in adults with obesity notably higher than results seen with currently approved agents
We want to help companies adjust to this shift as its happening
The FDA does not verify their safety or effectiveness
Diabetes 53 , 654662 (2004) T
US$ 26.99
US$ 21.47
US$ 26.21
US$ 29.97
US$ 29.39
